Ovid Therapeutics Inc.
Gaboxadol for therapeutic treatment of 1p36 deletion syndrome

Last updated:

Abstract:

Methods and pharmaceutical compositions containing gaboxadol or a pharmaceutically acceptable salt thereof for treating 1p36 deletion syndrome are provided.

Status:
Grant
Type:

Utility

Filling date:

18 Dec 2020

Issue date:

21 Jun 2022